Company description
At present, protein aggregation still remains a main area of focus in the production of monoclonal antibodies. Increasing the intrinsic properties of antibodies can promote manufacturability, attrition rates, formulation, safety, titers, immunogenicity, and solubility. On account of the identification of aggregation-prone regions and their contribution to the thermodynamic stability of the protein, predicting and decreasing the aggregation propensity of monoclonal antibodies become available. With years of exploration in antibody engineering, Creative Biolabs has built a full-scale in silico technology platform. Based on our advanced platform, we offer high quality antibody aggregation prediction services for customers all over the world.
